{"analyses":[{"ciLowerLimit":".46","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":".95","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.012","paramType":"Hazard Ratio (HR)","paramValue":"0.66","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.2","upperLimit":"8.8","value":"8.2"},{"groupId":"OG001","lowerLimit":"3.4","upperLimit":"8.1","value":"5.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"78"}],"units":"Participants"}],"description":"Progression free survival (PFS) was investigator assessed and is measured from the beginning of treatment until patient progression or death. Progression was determined using RECIST 1.1 criteria, progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).The primary analysis will be based on the stratified log-rank statistic to compare the two treatment arms on PFS. The Kaplan-Meier product-limit estimator will be used to estimate PFS distributions.Progression Free Survival was assessed per investigator, as this was the protocol-specified endpoint, and both investigator and independent review analyses of the PFS endpoint have been published","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 60mg cabozantinib-s-malate PO QD for 6 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm I (Cabozantinib-s-malate)"},{"description":"Patients receive 50mg sunitinib malate PO QD for 4 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Arm II (Sunitinib Malate)"}],"paramType":"MEDIAN","populationDescription":"All patients that were enrolled on to study.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"Months"}